Sign Out
There is insufficient information on the use of posaconazole in pregnant women. Studies in animals have shown reproductive toxicity. Posaconazole has been shown to cause skeletal malformations in rats at exposures lower than those obtained at therapeutic doses in humans. In rabbits, posaconazole was embryotoxic at exposures greater than those obtained at therapeutic doses. The potential risk for humans is unknown. Posaconazole should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Women of childbearing potential must be advised to always use effective contraceptive measure during treatment and for at least 2 weeks after completing therapy.
Posaconazole is excreted into the milk of lactating rats. The excretion of posaconazole in human breast milk has not been investigated. Posaconazole should not be used by nursing mothers unless the benefit clearly outweighs the risk to the infant.
Continue with Google